

# Renal Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/RA5BCE76D423EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: RA5BCE76D423EN

## Abstracts

The 7 major renal insufficiency markets reached a value of US\$ 9.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 22.7 Billion by 2034, exhibiting a growth rate (CAGR) of 8.6% during 2024-2034.

The renal insufficiency market has been comprehensively analyzed in IMARC's new report titled "Renal Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Renal insufficiency refers to a progressive and chronic condition in which the kidneys are unable to adequately perform their vital functions of filtering waste products and excess fluids from the blood. As a result, the illness causes a buildup of toxic substances, electrolyte imbalances, and fluid retention in the body. The symptoms of this ailment can vary depending on the severity of the ailment but may include fatigue, fluid retention, decreased urine output, swelling in the legs and ankles, memory problems, nausea, vomiting, loss of appetite, itching, shortness of breath, difficulty concentrating, skin rashes, confusion, etc. The diagnosis of renal insufficiency typically involves a combination of medical history review, clinical feature assessment, and a physical examination. Various blood workups, such as the serum creatinine test, complete blood count, blood urea nitrogen, etc., are commonly performed to evaluate kidney function and determine the underlying cause of the disease. The healthcare professional may also conduct imaging techniques, like computed tomography scans and magnetic resonance imaging, to visualize the structure of the kidneys and rule out other possible health problems.

The increasing cases of high blood pressure and diabetes, that can disrupt the blood vessels in the kidneys and impair their capability to filter waste and fluids effectively, are primarily driving the renal insufficiency market. In addition to this, the rising prevalence

of obstructions in the urinary tract, including tumors, kidney stones, an enlarged prostate, etc., which can obstruct urine flow, is creating a positive outlook for the market. Moreover, the widespread adoption of angiotensin-converting enzyme inhibitors and diuretics to reduce fluid retention and slow down the progression of the disease is further bolstering the market growth. In line with this, the inflating application of erythropoiesis-stimulating agents (ESAs), owing to their several benefits, like enhanced production of red blood cells, increased hemoglobin levels, improved energy, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of peritoneal dialysis techniques, since they allow for fewer dietary restrictions with greater flexibility and independence compared to conventional hemodialysis, is expected to drive the renal insufficiency market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the renal insufficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for renal insufficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the renal insufficiency market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the renal insufficiency market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the renal insufficiency market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current renal insufficiency marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the renal insufficiency market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the renal insufficiency market across the seven major

markets in 2023 and what will it look like in 2034?

What is the growth rate of the renal insufficiency market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of renal insufficiency across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of renal insufficiency by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of renal insufficiency by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with renal insufficiency across the seven major markets?

What is the size of the renal insufficiency patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of renal insufficiency?

What will be the growth rate of patients across the seven major markets?

### Renal Insufficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for renal insufficiency drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the renal insufficiency market?

What are the key regulatory events related to the renal insufficiency market?

What is the structure of clinical trial landscape by status related to the renal insufficiency market?

What is the structure of clinical trial landscape by phase related to the renal insufficiency

market?

What is the structure of clinical trial landscape by route of administration related to the renal insufficiency market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 RENAL INSUFFICIENCY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 RENAL INSUFFICIENCY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 RENAL INSUFFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 RENAL INSUFFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 RENAL INSUFFICIENCY - UNMET NEEDS**

## **10 RENAL INSUFFICIENCY - KEY ENDPOINTS OF TREATMENT**

## **11 RENAL INSUFFICIENCY - MARKETED PRODUCTS**

- 11.1 List of Renal Insufficiency Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 RENAL INSUFFICIENCY - PIPELINE DRUGS**

### 12.1 List of Renal Insufficiency Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. RENAL INSUFFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. RENAL INSUFFICIENCY – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 RENAL INSUFFICIENCY - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Renal Insufficiency - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Renal Insufficiency - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Renal Insufficiency - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Renal Insufficiency - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Renal Insufficiency - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 Renal Insufficiency - Market Size

#### 15.4.1.1 Market Size (2018-2023)

#### 15.4.1.2 Market Forecast (2024-2034)

### 15.4.2 Renal Insufficiency - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (2018-2023)

#### 15.4.2.2 Market Forecast by Therapies (2024-2034)

### 15.4.3 Renal Insufficiency - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 Renal Insufficiency - Market Size

#### 15.5.1.1 Market Size (2018-2023)

#### 15.5.1.2 Market Forecast (2024-2034)

### 15.5.2 Renal Insufficiency - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (2018-2023)

#### 15.5.2.2 Market Forecast by Therapies (2024-2034)

### 15.5.3 Renal Insufficiency - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 Renal Insufficiency - Market Size

#### 15.6.1.1 Market Size (2018-2023)

#### 15.6.1.2 Market Forecast (2024-2034)

### 15.6.2 Renal Insufficiency - Market Size by Therapies

#### 15.6.2.1 Market Size by Therapies (2018-2023)

#### 15.6.2.2 Market Forecast by Therapies (2024-2034)

### 15.6.3 Renal Insufficiency - Access and Reimbursement Overview

## 15.7 Market Scenario - Italy

### 15.7.1 Renal Insufficiency - Market Size

#### 15.7.1.1 Market Size (2018-2023)

#### 15.7.1.2 Market Forecast (2024-2034)

### 15.7.2 Renal Insufficiency - Market Size by Therapies

#### 15.7.2.1 Market Size by Therapies (2018-2023)

#### 15.7.2.2 Market Forecast by Therapies (2024-2034)

### 15.7.3 Renal Insufficiency - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Renal Insufficiency - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Renal Insufficiency - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Renal Insufficiency - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Renal Insufficiency - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Renal Insufficiency - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Renal Insufficiency - Access and Reimbursement Overview

## **16 RENAL INSUFFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 RENAL INSUFFICIENCY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 RENAL INSUFFICIENCY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Renal Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/RA5BCE76D423EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RA5BCE76D423EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

